Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Last Updated on: 22 February, 2024|Author: Getaka | Social: X Twitter Profile

Fundamental Analysis of Hester Biosciences Ltd

About the Company - Hester Biosciences Ltd

Hester Biosciences Ltd. is a Public Limited Listed company incorporated on 29/04/1987 and has its registered office in the State of Gujarat, India. Company’s Corporate Identification Number(CIN) is L99999GJ1987PLC022333 and registration number is 022333. Currently Company is involved in the business activities of Manufacture of medicinal substances used in the manufacture of pharmaceuticals: antibiotics, endocrine products, basic vitamins; opium derivatives; sulpha drugs; serums and plasmas; salicylic acid, its salts and esters; glycosides and vegetable alkaloids; chemically pure suger etc.. Company’s Total Operating Revenue is Rs. 219.35 Cr. and Equity Capital is Rs. 8.51 Cr. for the Year ended 31/03/2022.
Pharmaceuticals�Pushpak� 1st Floor, Panchvati Circle, Ahmedabad Gujarat
NamePosition Held
Dr. Bhupendra GandhiChairman
Mr. Rajiv GandhiManaging Director & CEO
Ms. Priya GandhiExecutive Director
Mr. Ravin GandhiDirector
Mr. Sanjiv GandhiDirector
Mr. Ashok BhadakalIndependent Director
Ms. Sandhya PatelIndependent Director
Mr. Ameet DesaiIndependent Director
Ms. Nina GandhiAlternate Director

Hester Biosciences Ltd. Share Price Update

Share PriceValue
Previous Day₹1,402.75

Basic Stock Data of Hester Biosciences Ltd

Market Cap 1,207 Cr.
Current Price 1,419
High / Low1,940/1,384
Stock P/E65.5
Book Value 331
Dividend Yield0.56 %
ROCE9.35 %
ROE9.86 %
Face Value 10.0

Data Source:

Hester Biosciences Ltd Quarterly Results

MonthSep 2020Dec 2020Mar 2021Jun 2021Sep 2021Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023
Operating Profit15.8121.1819.7817.0717.5615.0310.327.4312.7518.7611.6714.3613.22
OPM %29.60%37.23%30.82%28.36%28.02%26.99%18.28%14.65%17.43%25.03%17.34%16.35%18.76%
Other Income0.241.27-0.842.351.422.787.624.695.016.373.492.525.91
Profit before tax10.7017.6613.8715.3315.1911.6811.315.4610.2716.008.428.916.77
Tax %37.48%27.12%27.18%28.11%26.73%28.68%20.34%34.98%35.74%24.00%32.19%24.69%40.18%
Net Profit6.6812.8710.1011.0211.138.339.003.566.6012.165.716.714.04
EPS in Rs7.8514.5211.3914.6812.489.979.074.678.1613.155.336.904.81

Hester Biosciences Ltd Quarterly Chart

Hester Biosciences Ltd Profit & Loss

MonthMar 2012Mar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023TTM
Operating Profit19222425344147685569605158
OPM %39%34%36%28%34%33%35%38%30%32%26%19%19%
Other Income0013103761142018
Profit before tax12141318253136574150544040
Tax %37%37%31%26%23%26%36%28%25%31%26%30%
Net Profit79913192323413135392829
EPS in Rs8.9510.8911.1115.9922.5727.6830.1248.8734.2940.4746.2231.3030.19
Dividend Payout %7%18%18%19%18%19%33%23%19%25%22%26%

Hester Biosciences Ltd Profit & Loss Yearly Chart

Hester Biosciences Ltd Growth

Compounded Sales Growth
10 Years:15%
5 Years:14%
3 Years:13%
Compounded Profit Growth
10 Years:11%
5 Years:3%
3 Years:-3%
Stock Price CAGR
10 Years:32%
5 Years:1%
3 Years:-6%
1 Year:-19%
Return on Equity
10 Years:16%
5 Years:16%
3 Years:14%
Last Year:10%

Hester Biosciences Ltd Balance Sheet

MonthMar 2012Mar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Sep 2023
Equity Capital6999999999999
Other Liabilities1924192025253532657374116128
Total Liabilities95124142160186213244299387411562670683
Fixed Assets3938546065102110145142133237259248
Other Assets505768688589102148170169222237245
Total Assets95124142160186213244299387411562670683

Hester Biosciences Ltd Reserves and Borrowings Chart

Hester Biosciences Ltd Cash Flow

MonthMar 2012Mar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023
Cash from Operating Activity 1412920193538473758924
Cash from Investing Activity -10-23-15-21-13-30-26-21-73-42-117-77
Cash from Financing Activity -21077-72-11319-1811242
Net Cash Flow2-125-16128-17-23-12

Hester Biosciences Ltd Financial Efficiency Indicators

MonthMar 2012Mar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023
Debtor Days109857572957987671168486109
Inventory Days1,3517361,145431627376505540834452424399
Days Payable199135145681098410093261204101141
Cash Conversion Cycle1,2616851,074434614371491514690332409367
Working Capital Days204137194158188145150153169172204203
ROCE %20%20%18%15%19%19%20%26%16%18%14%9%

Hester Biosciences Ltd Financial Efficiency Indicators Chart

Hester Biosciences Ltd Share Holding Pattern

MonthDec 2020Mar 2021Jun 2021Sep 2021Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023
No. of Shareholders10,93010,50616,10816,39916,26915,01713,43913,71113,39113,12012,98413,342

Hester Biosciences Ltd Shareholding Pattern Chart

No. of Hester Biosciences Ltd Shareholders

Hester Biosciences Ltd Mutual Fund Holdings

Fund NameNo of SharesAUM (%)Amount Invested (Cr)
Motilal Oswal S&P BSE Healthcare ETF410.080.01

Hester Biosciences Ltd ROCE Trend

Hester Biosciences Ltd EPS Trend

Hester Biosciences Ltd Key Financial Ratios

MonthMar 23Mar 22Mar 21Mar 20Mar 19
Basic EPS (Rs.)32.9646.4140.7936.4447.84
Diluted EPS (Rs.)32.9646.4140.7936.4447.84
Cash EPS (Rs.)52.1065.4156.4451.8161.65
Book Value[Excl.RevalReserv]/Share (Rs.)339.19314.32277.37242.73212.95
Book Value[Incl.RevalReserv]/Share (Rs.)339.19314.32277.37242.73212.95
Revenue From Operations / Share (Rs.)312.79276.25251.95215.43209.32
PBDIT / Share (Rs.)77.3086.6686.2172.6188.45
PBIT / Share (Rs.)52.9767.1770.5657.2474.63
PBT / Share (Rs.)42.0262.3958.9048.5866.83
Net Profit / Share (Rs.)27.7745.9240.7936.4447.84
NP After MI And SOA / Share (Rs.)31.3046.4140.4734.2948.86
PBDIT Margin (%)24.7131.3734.2133.7042.25
PBIT Margin (%)16.9324.3128.0026.5735.65
PBT Margin (%)13.4322.5823.3722.5431.92
Net Profit Margin (%)8.8716.6216.1816.9122.85
NP After MI And SOA Margin (%)10.0016.8016.0615.9123.34
Return on Networth / Equity (%)9.5115.1815.0814.5023.42
Return on Capital Employeed (%)8.6412.2817.1616.0625.31
Return On Assets (%)3.977.028.377.5413.88
Long Term Debt / Equity (X)0.660.630.360.380.32
Total Debt / Equity (X)0.950.850.370.540.45
Asset Turnover Ratio (%)0.430.520.620.580.70
Current Ratio (X)1.532.012.631.912.91
Quick Ratio (X)0.961.231.621.141.87
Inventory Turnover Ratio (X)0.660.520.390.490.51
Dividend Payout Ratio (NP) (%)31.9421.5416.3020.4124.67
Dividend Payout Ratio (CP) (%)17.9715.1711.7614.0919.23
Earning Retention Ratio (%)68.0678.4683.7079.5975.33
Cash Earning Retention Ratio (%)82.0384.8388.2485.9180.77
Interest Coverage Ratio (X)7.0618.1411.118.3811.34
Interest Coverage Ratio (Post Tax) (X)3.5310.616.765.217.13
Enterprise Value (Cr.)1555.602514.681703.08877.851358.06
EV / Net Operating Revenue (X)5.8510.707.954.797.63
EV / EBITDA (X)23.6634.1123.2214.2118.05
MarketCap / Net Operating Revenue (X)4.869.837.614.297.38
Retention Ratios (%)68.0578.4583.6979.5875.32
Price / BV (X)4.628.887.143.917.41
Price / Net Operating Revenue (X)4.869.837.614.297.38

Hester Biosciences Ltd Profitability Ratios (%)

Hester Biosciences Ltd Liquidity Ratios

Hester Biosciences Ltd Liquidity Ratios (%)

Hester Biosciences Ltd Interest Coverage Ratios (%)

Hester Biosciences Ltd Valuation Ratios

Fair Value of Hester Biosciences Ltd Stock

Fair Value: ₹2149.67

The stock is undervalued by 51.49% compared to the current price ₹1419

*Investments are subject to market risks

Strength and Weakness of Hester Biosciences Ltd Stock

  1. The stock has a high average ROCE of 17.83%, which is a positive sign.
  2. The company has higher reserves (151.54 cr) compared to borrowings (110.85 cr), indicating strong financial stability.
  3. The company has shown consistent growth in sales (154.54 cr) and profit (33.15 cr) over the years.
  1. The stock is trading at a high valuation with an average P/B ratio of 64.51 and average Dividend Yield of 26.29%.
  2. The stock has a high average Working Capital Days of 173.08, which may not be favorable.
  3. The stock has a high average Cash Conversion Cycle of 409.08, which may not be favorable.

About the Author

Author Avatar

Getaka, CFA, a financial analyst with 15 years of experience in the industry. Getaka holds an MBA degree and the Chartered Financial Analyst designation, demonstrating his profound understanding of financial analysis and investment management. Throughout his career, he has conducted numerous financial analyses and due diligence processes for companies in the industry, and has a strong track record of identifying key trends and opportunities. He leverages his expertise to deliver a thorough financial analysis of a company, encompassing its financial performance, key ratios, future prospects, and risks. Getaka is committed to providing accurate, reliable, and trustworthy information to help readers make informed decisions about their finances and investments.

Disclaimer: This article is for informational purposes only and should not be construed as financial advice. The author is not a SEBI registered financial advisor and does not have any vested interest in Hester Biosciences Ltd. Investors are advised to conduct their own due diligence and consult with a financial professional before making any investment decisions. The information provided in this article is based on publicly available data and the author's analysis, but it may not be comprehensive or up-to-date. The author and are not responsible for any errors or omissions in the content. This article is not intended to promote any particular investment strategy or recommendation, and readers should consult with their own financial advisors before making any investment decisions. Data Source: NSE